Dragovic, G. (23396934400)G. (23396934400)DragovicMilk, N. (8633711100)N. (8633711100)MilkJevtovic, D.J. (55410443900)D.J. (55410443900)Jevtovic2025-06-132025-06-132005https://doi.org/10.1258/0956462054094042https://www.scopus.com/inward/record.uri?eid=2-s2.0-20944442696&doi=10.1258%2f0956462054094042&partnerID=40&md5=34eeb7cc83b06821c2e3beb17074553fhttps://remedy.med.bg.ac.rs/handle/123456789/11110Acute pancreatitis (AP) is a well-known adverse effect of nucleoside reverse transcriptase inhibitors (NRTIs). Therefore, we performed a prospective, cohort study to examine the incidence rates (IRs) and rate ratios (RRs) of AP for each NRTI. A total of 116 HIV patients were included in the final analysis comprising 445.6 person-years of follow-up. Twelve cases of AP were recorded. The lowest IR for AP was for didanosine (ddI) (IR = 0.03 per 100 person-years, 95% confidence interval [CI] = 0.01-0.05), and the highest for ddI + stavudine (d4T) (IR = 0.08, 95% CI = 0.07-012). Compared with ddl alone, the RR of AP was 2.21 (95% CI = 1.32-9.31) for d4T, and 3.13 (95% CI = 1.43-12.56) for ddI + d4T. Other risk factors for AP were CD4 cell count <200 cells/mm 3 and female sex. Our results suggest that the use of d4T alone or combined with ddI should not be used as first-line therapy, especially in women or patients with CD4-cell count <200 cells/mm 3 .Acute pancreatitisDidanosineNucleoside reverse transcriptase inhibitorsStavudine